Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel
- Study type
- Clinical guideline
- Study name
- ELN 2024 (ALL)
- Design
- Consensus recommendations of the European working group for adult ALL within the European LeukemiaNet (ELN)
- Source
- Blood · 2024
In plain words
This European guideline explains how ALL in adults should be diagnosed, which genetic tests are needed and how the risk of the disease is assessed. The most important predictor is the response to treatment measured by a very sensitive test for remaining disease (MRD).
Study population
Adults with acute lymphoblastic leukaemia (ALL).
Clinical significance and place in guidelines
Sets European standards for the diagnosis and risk classification of adult ALL and recommends MRD testing in all patients for risk stratification; treatment recommendations are given in the companion paper ("Management of ALL in adults: 2024 ELN recommendations").
Limitations
Based on the consensus of European experts and should be complemented by the experience of national groups.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.